Evaluate Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

October 23, 2007

Primary Completion Date

December 1, 2007

Study Completion Date

December 12, 2007

Conditions
Influenza
Interventions
BIOLOGICAL

GSK Biologicals' influenza vaccine GSK576389A

Single dose, intramuscular injection

BIOLOGICAL

Fluarix™

Single dose, intramuscular injection

Trial Locations (1)

9000

GSK Investigational Site, Ghent

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY